Gilead Q4 Earnings Highlights: Remdesivir Sales Fall 30%, Raises Dividend, FY22 EPS Below Estimates
Gilead Sciences Inc (NASDAQ: GILD) posted
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
All news is property of their respective owners.
